Nine Square Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Nine Square Therapeutics was a biotechnology company discovering small-molecule drugs for neurodegenerative diseases, initially focused on Parkinson's disease, ALS, and lysosomal storage diseases. Founded in 2020 by life sciences venture firm Apple Tree Partners and scientists at the University of California, San Francisco, its platform combined phenotypic image-based cell profiling, computational chemistry, and machine learning to accelerate drug discovery — including Parkin activators that clear dysfunctional mitochondria to protect neurons. It raised about $55 million, including a $4.5 million grant from the Michael J. Fox Foundation in 2023. On January 1, 2026, the company filed for Chapter 11 bankruptcy in Delaware.
02 / Nine Square Therapeutics FAILURE REASONS
Failure reasons
No public statement of the failure's cause has been disclosed; the Chapter 11 filing is the documented outcome. Nine Square's trajectory fits a familiar pattern for platform-stage biotechs of its vintage: a capital-intensive discovery engine in neurodegeneration — one of drug development's highest-risk areas — raised in the 2020–2021 biotech boom and facing a much colder funding market by 2024–2025, with no program disclosed as having reached clinical-stage milestones that could support the next financing. The bankruptcy case, filed January 1, 2026, remains open.
03 / EVENT HISTORY
Events in the structured record
- Founded
Nine Square Therapeutics was founded by Apple Tree Partners and UCSF scientists to discover small-molecule drugs for neurodegenerative diseases.
- $4.5M grant
The company was awarded a $4.5 million grant from the Michael J. Fox Foundation to advance its Parkin activator program for Parkinson's disease.
- Chapter 11 bankruptcy
On January 1, 2026, Nine Square Therapeutics filed a voluntary Chapter 11 petition in the District of Delaware (case 26-10001); the case is open.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
On January 1, 2026, Nine Square Therapeutics filed a voluntary Chapter 11 petition in the US Bankruptcy Court for the District of Delaware (case 26-10001).
- 02
The case is reported as open; monitoring and docket updates are handled through the bankruptcy court proceedings.